---
id: aace-thyroid-nodule-2024
title: "AACE 2024 Clinical Practice Guideline: Thyroid Nodule Evaluation and Thyroid Cancer Management"
short_title: "AACE Thyroid Nodule 2024"

organization: American Association of Clinical Endocrinology
collaborators: null
country: US
url: https://www.aace.com/guidelines
doi: null
pmid: null
open_access: true

specialty: endocrinology
guideline_type: clinical-practice
evidence_system: AACE
conditions:
  - thyroid nodule
  - thyroid cancer
  - differentiated thyroid cancer
tags:
  - ultrasound
  - FNA biopsy
  - molecular testing
  - radioactive iodine
  - levothyroxine

publication_date: 2024-06-01
previous_version_date: 2022-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 AACE clinical practice guideline on the evaluation of thyroid nodules and management of differentiated thyroid cancer.

## Key Recommendations

### Thyroid Nodule Evaluation
- **Thyroid Ultrasound**: First-line for all palpable nodules or incidental findings.
- **Risk Stratification**: Use standardized ultrasound classification (ACR TI-RADS, EU-TIRADS, ATA).
- **TSH**: Measure in all patients with thyroid nodules.

### Fine-Needle Aspiration (FNA)
- Based on nodule size and ultrasound features:
  - High suspicion: FNA if ≥1 cm.
  - Intermediate suspicion: FNA if ≥1.5 cm.
  - Low suspicion: FNA if ≥2 cm (or observe).
  - Very low suspicion/benign: FNA generally not needed.
- Bethesda classification for cytology.

### Molecular Testing
- Consider for indeterminate cytology (Bethesda III/IV) to guide surgery vs. surveillance.
- Gene expression classifiers, mutation panels.

### Differentiated Thyroid Cancer (DTC) Management

#### Surgery
- **Total Thyroidectomy**: For tumors >4 cm, extrathyroidal extension, metastatic disease.
- **Lobectomy**: May be sufficient for low-risk, unifocal papillary thyroid cancer ≤4 cm without aggressive features.
- **Lymph Node Dissection**: Central compartment dissection for clinically/radiographically positive nodes.

#### Radioactive Iodine (RAI)
- **Adjuvant RAI Ablation**: For high-risk DTC (extrathyroidal extension, LN metastases, distant metastases).
- NOT routine for low-risk DTC (small tumors, intrathyroidal, no aggressive features).

### TSH Suppression
- Levothyroxine to suppress TSH:
  - High-risk: TSH <0.1 mU/L.
  - Intermediate: TSH 0.1-0.5 mU/L.
  - Low-risk: TSH 0.5-2 mU/L (less aggressive suppression).

### Surveillance
- Thyroglobulin levels, neck ultrasound.
